Company profile
Incannex Healthcare Inc.
NASDAQ:IXHLBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05857384 | phase1 | completed | 2023-09-08 | 2024-07-31 | Incannex Healthcare Ltd | Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs |
| NCT07635563 | phase2 | recruiting | 2026-07-21 | 2027-04-01 | Incannex Healthcare Ltd | DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea. |
| NCT06146101 | phase2_3 | completed | 2024-05-02 | 2025-05-20 | Incannex Healthcare Ltd | RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA |
| NCT05942911 | phase2 | terminated | 2023-11-22 | 2024-10-28 | Incannex Healthcare Ltd | Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis |
FDA applications (0)
No records yet.